Leveraging Geospatial and Environmental Data for Precision Oncology in Underserved Populations
- maninon0
- Jul 18
- 1 min read
Updated: Jul 23
Better trials start with everyone In.
Clinical trials can’t afford to overlook the very people they aim to help. Underrepresentation doesn’t just raise equity concerns—it weakens data, drives up costs, and limits the real-world impact of therapies.
Our latest white paper introduces the TRIDENT Rubix LS Model—a patient-first, equity-driven approach designed to improve retention, build long-term trust, and generate more meaningful outcomes.
Learn how Patient X and real-world insights are reshaping trial design—moving from one-size-fits-all to community-centered, smarter studies.
